SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product ...
SpringWorks Therapeutics reports FY24 EPS ($3.48), consensus ($3.16)
Reports FY24 revenue $191.5M, consensus $190.85M. “We are very pleased with the strong execution of OGSIVEO in 2024 and believe that we are ...
manilatimes3d
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics
"Onco360 is grateful for the opportunity to partner on another therapy with the team at SpringWorks Therapeutics and become a ...
Stocktwits on MSN18h
SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect
SpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor ...
Managed Healthcare Executive6d
FDA Approves Gomekli, First and Only NF1-PN Treatment for Both Children and Adults
Gomekli is the second ever FDA-approved treatment for rare tumor disease, NF1-PN and the first to be approved for both adult ...
Healio3d
FDA approves Gomekli for neurofibromatosis type 1 with plexiform neurofibromas
The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...
C&EN6d
FDA approves drug for neurofibromatosis
The US Food and Drug Administration has approved mirdametinib for the treatment of neurofibromatosis type 1 (NF1) in adults ...
Top 3 Health Care Stocks You May Want To Dump In February
As of Feb. 20, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum ...
Why SpringWorks Therapeutics, Inc. (SWTX) is the Best Performing Healthcare Stock So Far in 2025
We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...